| |
|
Product Name:
|
CAREC M2-09
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Flaviviridae, Flavivirus
Species: Yellow fever virus
Strain/Isolate: CAREC M2-09
|
|
Additional Information:
|
YFV is a mosquito-borne virus, which circulates in natural transmission cycles between mosquitoes and temporary amplifiers, humans and monkeys. Yellow fever (YF) is endemic in tropical regions of Africa and South America and poses a serious health risk to travelers to these areas.3,4 Vector-control strategies that were once successful for elimination of YFV from many regions have faltered, leading to reemergence of the disease.5 Currently, there is no effective drug treatment for YF; however, live-attenuated 17D YF vaccines have demonstrated high rates of effectiveness and good safety profiles.6,7,8
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney epithelial cells (Vero; ATCC® CCL-81™) infected with YFV, CAREC M2-09.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-50062 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Chlorocebus aethiops kidney epithelial cells (Vero; ATCC® CCL-81™)
Growth Medium: Eagle’s Minimum Essential Medium containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1.5 g/L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent
Infection: Cells should be 60% to 80% confluent
Incubation: 5 to 7 days at 37°C and 5% CO2
Cytopathic Effect: Cell enlargement, rounding and detachment
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Tesh, R. B., Personal Communication.
2. Auguste, A. J., et al. “Yellow Fever Virus Maintenance in Trinidad and Its Dispersal throughout the Americas.” J. Virol. 84 (2010): 9967-9977. PubMed: 20631128.
3. Barrett, A. D. T. and S. Higgs. “Yellow Fever: A Disease that Has Yet to Be Conquered.” Annu. Rev. Entomol. 52 (2007): 209–229. PubMed: 16913829.
4. Bryant, J. E., E. C. Holmes, and A. D. T. Barrett. “Out of Africa: A Molecular Perspective on the Introduction of Yellow Fever Virus into the Americas.” PLoS Pathog. 3 (2007): e75. PubMed: 17511518.
5. Barnett, E. D. “Yellow Fever: Epidemiology and Prevention.” Clin. Infect. Dis. 44 (2007): 850–856. PubMed: 17304460.
6. Barrett, A. D. T., et al. “17D Yellow Fever Vaccines: New Insights. A Report of a Workshop Held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005.” Vaccine 25 (2007): 2758–2765. PubMed: 17368349.
7. Monath, T. P., et al. “Yellow Fever 17D Vaccine Safety and Immunogenicity in the Elderly.” Hum. Vaccin. 1 (2005): 207–214. PubMed: 17012867.
8. Pugachev, K. V., F. Guirakhoo, and T. P. Monath. “New Developments in Flavivirus Vaccines with Special Attention to Yellow Fever.” Curr. Opin. Infect. Dis. 18 (2005): 387–394. PubMed: 16148524.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH, as part of the WRCEVA program: Yellow Fever Virus, CAREC M2-09, NR-50062.”
|
|
Biosafety Level:
|
3
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|